Cello Health has announced further expansion in the United States with the acquisition of New Jersey-based company Defined Healthcare Research (Defined Health).
Defined Health, founded in 1983, is a business development strategy firm servicing life sciences firms with a particular focus in biotech. The company helps clients build and strengthen portfolios and platforms with services focused on defining value for early stage compounds.
Defined Health will work closely with Cello Health’s consulting capability Cello Health Consulting, especially in early asset development and commercialisation, while providing further depth to its services through Cello Health’s US capabilities in Communications and Insight, and specific Cello Health services in areas such as market access.
Stephen Highley, Chairman of Cello Health, said: "Understanding the commercial opportunity and applicability of early stage assets is of fundamental importance to our clients and Defined Health positions Cello Health to be able to deliver to this requirement."
Julia Ralston, CEO, Cello Health US, said: “The acquisition of Defined Health is an excellent strategic fit as we continue our expansion in the US, strengthening our focus on early drug development and complementing our three core capabilities in Insight, Consulting and Communications."